Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited Telix is a clinical-stage biopharmaceutical company developing diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR).

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic oncology products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in onc

ology and rare diseases. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report adverse reactions to Telix by calling 1-844-455-8638 or emailing pharmacovigilance@telixpharma.com. Please see full Illuccix Prescribing Information:https://illuccixhcp.com/wp-content/uploads/illuccix-prescribing-information.pdf

20/08/2025

Telix has released its results for the half-year ended 30 June 2025.

H1 2025 was a period of rapid transformation for the Company, with strong revenue growth delivered alongside investments in global manufacturing, new product launches, and pipeline expansion. These initiatives have positioned Telix for sustainable, long-term growth.

To learn more about the results, visit our website, where you can also register for an investor webcast this morning AEST, and later today in Europe and the US: https://telixpharma.com/news-views/telix-2025-half-year-results-strong-commercial-performance-enables-investment-for-long-term-growth/

Join Telix this week at the 25th Asia-Pacific Prostate Cancer Conference in Sydney, Australia.This year’s program will f...
19/08/2025

Join Telix this week at the 25th Asia-Pacific Prostate Cancer Conference in Sydney, Australia.

This year’s program will feature presentations on Telix’s Phase 3 ProstACT Global study and SENSEI® miniature drop-in gamma probe for radio-guided surgery, alongside a range of workshops and discussions advancing prostate cancer care.

We’re proud to support this important event. Workshop places are limited so secure your spot today: https://www.prostatecancerconference.org.au/

Illuccix® (kit for the preparation of 68Ga-PSMA-11 injection*) is now listed on the Medicare Benefits Schedule in Austra...
05/08/2025

Illuccix® (kit for the preparation of 68Ga-PSMA-11 injection*) is now listed on the Medicare Benefits Schedule in Australia for selection of patients’ suitability for lutetium-177 PSMA therapy.

Swipe to hear from Anne Savage, CEO of the Cancer Foundation of Australia, on what this means for Australian men with advanced prostate cancer.

Specialists and consultant physicians can request an Illuccix PSMA-PET scan for patients with metastatic castrate resistant prostate cancer, to determine eligibility for lutetium therapy.

Visit https://www.mbsonline.gov.au/ for further information.

*also known as Ga-68 Glu-urea-Lys(ahx)-hbed-CC.

Telix will release its H1 2025 results on Thursday 21 August 2025.An investor webcast will be held at 9:30am AEST (7:30p...
29/07/2025

Telix will release its H1 2025 results on Thursday 21 August 2025.

An investor webcast will be held at 9:30am AEST (7:30pm EDT, Wednesday 20 August).

To register for the webcast visit: https://bit.ly/4ocfdgL

27/07/2025

Sarcoma Awareness Month reminds us how much work remains in tackling rare cancers like soft tissue sarcoma (STS).

While localized STS can often be managed with radiotherapy, treatment becomes significantly more difficult once the disease spreads.

In this video, ZOLAR Principal Investigator, Professor Rodney Hicks AM, explains how a radiolabelled antibody presents a novel mechanism of action by targeting PDGFRα, a protein frequently overexpressed in STS.

Based on a theranostic approach, Telix’s ZOLAR trial is using TLX300-CDx (⁸⁹Zr-olaratumab) PET imaging to assess PDGFRα expression and evaluate potential effectiveness in treating patients with advanced disease, prior to commencing therapeutic studies.

Read more about ZOLAR here: https://telixpharma.com/news-views/telix-announces-first-patient-dosed-in-first-in-human-zolar-trial-of-tlx300-cdx-in-advanced-soft-tissue-sarcoma/

TLX300-CDx has not received a marketing authorization in any jurisdiction.

, ,

Telix is proud to support the 25th Asia-Pacific Prostate Cancer Conference, taking place from 21–23 August in Sydney, Au...
25/07/2025

Telix is proud to support the 25th Asia-Pacific Prostate Cancer Conference, taking place from 21–23 August in Sydney, Australia.

Our Phase 3 ProstACT Global study for prostate cancer therapy will be highlighted throughout the event, and we’re excited to present workshops on radiation oncology and robotics, featuring PSMA radioguided surgery using Telix’s SENSEI® miniature drop-in gamma probe.

Targeted radionuclide therapies will also be a key focus of the Nursing and Allied Health program.

Workshop spaces are filling fast, so secure your spot today: https://www.prostatecancerconference.org.au/

Telix today provides a revenue and business update for the second quarter of 2025.Unaudited total revenue for the quarte...
22/07/2025

Telix today provides a revenue and business update for the second quarter of 2025.

Unaudited total revenue for the quarter was US$204 million, representing a 63% increase year-over-year.

This was primarily driven by continued strong sales of Telix’s prostate cancer imaging product, Illuccix®.

Positive momentum continues across multiple assets in Telix’s therapeutic pipeline, including the achievement of a key recruitment milestone in the ProstACT Global Phase 3 trial.

For more details on our Q2 2025 results, visit: https://telixpharma.com/news-views/telix-reports-204m-revenue-up-63-yoy/

This Sarcoma Awareness Month, we’re shining a spotlight on soft tissue sarcoma (STS) - a rare and often overlooked cance...
21/07/2025

This Sarcoma Awareness Month, we’re shining a spotlight on soft tissue sarcoma (STS) - a rare and often overlooked cancer that affects people of all ages.

With over 70 different subtypes, STS presents a complex diagnostic and treatment challenge, with many patients facing limited treatment options and delayed diagnosis.

At Telix, we’re committed to advancing therapeutics and diagnostics that improve outcomes for patients with rare cancers like STS.

In our phase 1 ZOLAR trial, we are aiming to validate the use of radiolabeled olaratumab, an antibody exclusively licensed from Lilly, as a potential treatment for advanced, metastatic STS.

To learn more about ZOLAR, visit our website here: https://www.linkedin.com/posts/telixpharma_a-first-patient-has-been-dosed-in-telixs-activity-7312927079300222976-DQyg?utm_source=share&utm_medium=member_desktop&rcm=ACoAABkhILYBczBXgbnwX4_yIKLZ9Tc4cuKxP1o

, ,

TX300-CDx has not received a marketing authorization in any jurisdiction.

Telix recently supported the National Brain Tumor Society’s Glioblastoma Awareness Day on Capitol Hill, standing alongsi...
18/07/2025

Telix recently supported the National Brain Tumor Society’s Glioblastoma Awareness Day on Capitol Hill, standing alongside patients, advocates, and lawmakers to honor those affected by GBM.

The courage of those who shared their experiences was a powerful call to action, with each testimony underscoring the urgent need to prioritize brain cancer research.

Many of the lawmakers in the room had been personally affected by GBM and together they are pushing forward the BRAIN Act (H.R.2767/S.1330), a piece of legislation that Telix supports with the mutual goal of access to biomarker testing and imaging.

18/07/2025

Gute Nachrichten!

Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been approved in Austria.

With its broad indication, Illuccix® is designed to help healthcare providers deliver efficient, reliable imaging. The approval comes as demand for PSMA-PET continues to grow across Europe, highlighting the need for solutions that fit within hospital workflows.

Healthcare professionals in Austria interested in ordering Illuccix® or learning more about availability can contact Telix’s local distributor, THP Medical Products : orders.nuk@thp.at

Read more on our website here: https://telixpharma.com/news-views/telixs-illuccix-psma-pet-imaging-agent-approved-in-italy-2/

🧠 July 16 is Glioblastoma (GBM) Awareness Day - a moment to honor those affected by one of the most aggressive and compl...
15/07/2025

🧠 July 16 is Glioblastoma (GBM) Awareness Day - a moment to honor those affected by one of the most aggressive and complex brain cancers.

It’s also a time to reflect on how we can do better.

Despite ongoing research, treatment options for GBM remain limited with poor patient outcomes.

At Telix, our mission is to improve patient outcomes by advancing our theranostic brain cancer candidates. By combining targeted radiopharmaceutical therapeutics with diagnostic imaging, we aim to help physicians improve the way they see, track and treat GBM.

U.S. Healthcare professionals can dive deeper into the diagnostic challenges in gliomas here: https://gliomagrayareas.com

And to learn more about Telix’s brain portfolio, visit: telixpharma.com/brain

Gozellix® (kit for preparing gallium-68 gozetotide injection), has been granted a permanent HCPCS code by the U.S. Cente...
09/07/2025

Gozellix® (kit for preparing gallium-68 gozetotide injection), has been granted a permanent HCPCS code by the U.S. Centers for Medicare & Medicaid Services (CMS).

Effective from 1 October 2025, CMS and commercial health insurers will recognise the HCPCS Level II code A9616 assigned for reimbursement of Gozellix.

The assignment of the code is a significant milestone supporting provider billing and reimbursement for Gozellix, and a further step toward receiving Transitional Pass-Through (TPT) payment status.

Read more on our website here: https://telixpharma.com/news-views/gozellix-receives-permanent-hcpcs-code/

Address

Melbourne, VIC

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Website

Alerts

Be the first to know and let us send you an email when Telix Pharmaceuticals Limited posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Telix Pharmaceuticals Limited:

Shortcuts

Featured

Share

Our Story

Telix Pharmaceuticals Limited was established in January 2017. We are a clinical-stage biotechnology company developing a pipeline of molecularly-targeted radiation (MTR) therapies to image and treat cancer. Our team is an experienced group of biopharma clinicians and executives, with a passion for radiation biology and oncology.

In December 2018, Telix acquired ANMI SA, a leader in the field of radiopharmaceutical development. The ANMI team brings a wealth of innovation and experience in the streamlined development and production of novel radiopharmaceuticals. For more information about ANMI, visit anmi.be.

Our products currently focus on unmet needs in cancer care, specifically in:


  • Prostate